Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 372-380

  Jurcic, Joseph G ^a,c   DeBlasio, Tony ^a   Dumont, Larry ^b   Yao, Tzy Jyun ^a   Scheinberg, David A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b PROTEIN DESIGN LABS INC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN; MONOCLONAL ANTIBODY M 195; RETINOIC ACID;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEVER; FOLLOW UP; HUMAN; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; TIME FACTORS; TRETINOIN;

EID: 0033982749     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. de Thé, H., Chomienne, C., Lanotte, M., Degos, L., and Déjean, A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature (Lond.), 347: 558-561, 1990.
2. Kakizuka, A., Miller, W. H., Jr., Umesono, K., Warrell, R. P., Jr., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., and Evans, R. M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR-α with a novel putative transcription factor, PML. Cell, 66: 663-674, 1991.
3. de Thé, H., Lavau, C., Marcio, A., Chomienne, C., Degos, L., and Déjean A. The PML-RAR-α fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell, 66: 675-684, 1991.
4. Biondi, A., Rambaldi, A., Alcalay, M., Pandolfi, P. P., LoCoco, F., Diverio, D., Rossi, V., Mencarelli, A., Longo, L., Zangrilli, D., Masera, G., Tiziano, B., Mandelli, F., Grignani, F., and Pelicci, P. G. RAR-α rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. Blood, 77: 1418-1422, 1991.
5. Miller, W. H., Jr., Kakizuka, A., Frankel, S. R., Warrell, R. P., Jr., DeBlasio, A., Levine, K., Evans, R. M., and Dmitrovsky, E. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA, 89: 2694-2698, 1992.
6. Castaigne, S., Balitrand, N., de Thé, H., Déjean, A., Degos, L., and Chomienne, C. A PML/retinoic acid receptor-α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood, 79: 3110-3115, 1992.
7. Borrow, J., Goddard, A. D., Gibbons, B., Kapz, F., Swirsky, D., Fioretos, T., Dube, I., Winfield, D. A., Kingston, J., Hagemeijer, A., Rees, J. K., Lister, T. A., and Solomon, E. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RAR-PML fusion transcripts. Br. J. Haematol., 82: 529-540, 1992.
8. LoCoco, F., Diverio, D., Pandolfi, P. P., Biondi, A., Rossi, V., Avvisati, G., Rambaldi, A., Arcese, W., Petti, M. C., and Meloni, G. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet, 340: 1437-1438, 1992.
9. Miller, W. H., Jr., Levine, K., DeBlasio, A., Frankel, S. R., Dmitrovsky, E., and Warrell, R. P., Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood, 82: 1689-1694, 1993.
10. Huang, W., Sun, G-L., Li, Z-S., Cao, Q., Lu, Y., Jang, G-S., Zhang, F-Q., Chai, J-R., Wang, Z-Y., Waxman, S., Chen, Z., and Chen, S-J. Acute promyelocytic leukemia: clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood, 82: 1264-1269, 1993.
11. Jurcic, J. G., Miller, W. H., Jr., DeBlasio, A., Scheinberg, D. A., and Warrell, R. P., Jr. Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia. Blood, 88: 635a, 1996.
12. Diverio, D., Rossi, V., Avvisati, G., DeSantis, S., Pistilli, A., Pane, F., Saglio, G., Martinelli, G., Petti, M. C., Santoro, A., Pelicci, P. G., Mandelli, F., Biondi, A., and LoCoco, F., for the GIMEMA and AIEOP Cooperative Groups. Early detection of relapse by prospective reverse transcription-polyrnerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood, 92: 784-789, 1998.
13. Huang, M. E., Ye, Y. C., Chen, S. R., Chai, J. R., Lu, J. X., Lin, Z., Zhoa, L., Gu, L. J., and Wang, Z-Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72: 567-572, 1988.
14. Castaigne, S., Chomienne, C., Daniel, M. T., Berger, R., Fenaux, P., and Degos, L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 76: 1704-1709, 1990.
15. Warrell, R. P., Jr., Frankel, S. R., Miller, W. H., Jr., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., Gabrilove, J., Gordon, M. S., and Dmitrovsky, E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med., 324: 1385-1393, 1991.
16. Benedetti, F., Tong, W., Jurcic, J., Gill, G., Truglia, J., and Warrell, R. P., Jr. Clinical activity and pharmacology of 9-cis retinoic acid in patients with acute promyelocytic leukemia. Proc. Am. Soc. Clin. Oncol., 75: 359, 1996.
17. Scheinberg, D. A., Tanimoto, M., McKenzie, S., Strife, A., Old, L. J., and Clarkson, B. D. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia (Baltimore), 3: 440-445, 1989.
18. Sabbath, K. D., Ball, E. D., Larcom, P., Davis, R. B., and Griffin, J. D. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J. Clin. Investig., 75: 746-753, 1985.
19. Griffin, J. D., Linch, D., Sabbath, K. D., Larcom, P., and Schlossman, S. F. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res., 8: 521-534, 1984.
20. Andrews, R. G., Takahashi, M., Segal, G. M., Powell, J. S., Bernstein, I. D., and Singer, J. W. The L4F3 antigen is expressed by unipotent colony-forming cells but not by their precursors. Blood, 68: 1030-1035, 1986.
21. Scheinberg, D. A., Lovett, D., Divgi, C. R., Graham, M. C., Berman, E., Pentlow, K., Feirt, N., Finn, R. D., Clarkson, B. D., Gee, T. S., Larson, S. M., Oettgen, H. F., and Old, L. J. A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol., 9: 478-490, 1991.
22. Schwartz, M. A., Lovett, D. R., Redner, A., Finn, R. D., Graham, M. C., Divgi, C. R., Dantis, L., Gee, T. S., Andreeff, M., Old, L. J., Larson, S. M., and Scheinberg, D. A. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol., 11: 294-303, 1993.
23. Jurcic, J. G., Caron, P. C., Nikula, T. K., Papadopoulos, E. B., Finn, R. D., Gansow, O. A., Miller, W. H., Jr., Geerlings, M. W., Warrell, R. P., Jr., Larson, S. M., and Scheinberg, D. A. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res., 55 (Suppl.): 5908s-5910s, 1995.
24. Jurcic, J. G., Caron, P. C., Miller, W. H., Jr., Yao, T. J., Maslak, P., Finn, R. D., Larson, S. M., Warrell, R. P., Jr., and Scheinberg, D. A. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia (Baltimore), 9: 244-248, 1995.
25. Co, M. S., Avdalovic, N. M., Caron, P. C., Avdalovic, M. V., Scheinberg, D. A., and Queen, C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol., 148: 1149-1154, 1991.
26. Caron, P. C., Co, M. S., Bull, M. K., Avdalovic, N. M., Queen, C., and Scheinberg, D. A. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res., 52: 6761-6767, 1992.
27. Caron, P. C., Jurcic, J. G., Scott, A. M., Finn, R. D., Divgi, C. R., Graham, M. C., Jureidini, I. M., Sgouros, G., Tyson, D., Old, L. J., Larson, S. M., and Scheinberg, D. A. A Phase IB trial of humanized antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood, 83: 1760-1768, 1994.
28. Caron, P. C., Dumont, L., and Scheinberg, D. A. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin. Cancer Res., 4: 1421-1428, 1998.
29. Cheson, B. D., Cassileth, P. A., Head, D. R., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning, R., Gale, R. P., Grever, M. R., and Keating, M. J. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol., 8: 813-819, 1990.
30. LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., and Khazaeli, M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA, 86: 4220-4224, 1989.
31. Frankel, S. R., Eardley, A., Heller, G., Berman, E., Miller, W. H., Jr., Dmitrovsky, E., and Warrell, R. P., Jr. All-trans retinoic acid for acute promyelocytic leukemia. Ann. Intern. Med., 120: 278-286, 1994.
32. Soignet, S., Fleischauer, A., Polyak, T., Heller, G., and Warrell, R. P., Jr. All-trans retinoic acid significantly increases five year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother. Pharmacol., 40 (Suppl): S25-S29, 1997.
33. Diverio, D., Pandolfi, P. P., Biondi, A., Avvisati, G., Petti, M. C., Mandelli, F., Pelicci, P. G., and LoCoco, F. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood, 82: 3556-3559, 1993.
34. Mandelli, F., Diverio, D., Avvisati, G., Luciano, A., Barbui, T., Bernasconi, C., Broccia, G., Cerri, R., Falda, M., Fioritoni, G., Leoni, F., Liso, V., Petti, M. C., Rodeghiero, F., Saglio, G., Vegna, M. L., Visani, G., Jehn, U., Willemze, R., Muus, P., Pelicci, P. G., Biondi, A., and LoCoco, F., for the GIMEMA and AIEOP Cooperative Groups. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood, 90: 1014-1021, 1997.
35. Fenaux, P., Castaigne, S., Dombret, H., Archimbaud, E., Cuarte, M., Morel, P., Lamy, T., Tilly, H., Guerci, A., Maloisel, F., Bordessoiule, D., Sadoun, A., Tiberghien, P., Fegueux, N., Daniel, M. T., Chomienne, C., and Degos, L. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood, 80: 2176-2181, 1992.
36. Fenaux, P., LeDeley, M. C., Castaigne, S., Archibaud, E., Chomienne, C., Link, H., Guerci, A., Duarte, M., Daniel, M. T., Bowen, D., Huebner, G., Bauters, F., Fegueux, N., Fey, M., Sanz, B., Lowenberg, B., Maloisel, F., Auzanneau, G., Sadoun, G., Gardin, C., Bastion, Y., Ganser, A., Jacky, E., Dombret, H., Chastang, C., and Degos, L., for the European APL 91 Group. Effect of all-trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood, 82: 3241-3249, 1993.
37. Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., and Wiernik, P. H. All-trans retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med., 337: 1021-1028, 1997.
38. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombert, H., Archimbaud, E., Fey, M., Rayon, C., Huguet, F., Sotto, J-J., Gardin, C., Makhoul, P. C., Travade, P., Solary, E., Fegueux, N., Bordessoule, D., San Miguel, J., Link, H., Desablens, B., Stamatoullas, A., Deconinck, E., Maloisel, F., Castaigne, S., Preudhomme, C., and Degos, L., for the European APL Group. A randomized comparison of all-trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood, 94: 1192-1200, 1999.
39. Weisburg, J. H., Roepe, P. D., Dzekunov, S., and Scheinberg, D. A. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J. Biol. Chem., 274: 10877-10888, 1999.
40. Soignet, S. L., Maslak, P., Wang, Z-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., Pandolfi, P. P., and Warrell, R. P., Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 339: 1341-1348, 1998.